Polyrizon Publishes U.S. Patent Application for Nasal Drug Delivery Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2026
0mins
Polyrizon announced the publication of U.S. patent application No. US 2024/0358741 A1, titled "Mucoadhesive Polymers for Nasal Drug Delivery". The patent application covers Polyrizon's proprietary Trap & Target mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients through the nasal route.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLRZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLRZ
About PLRZ
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
Polyrizon Receives Notice of U.S. Patent Application for Drug Delivery Technology
- Patent Application Announcement: Polyrizon announced the receipt of a U.S. patent application notice for its Trap & Target mucoadhesive polymer technology, aimed at enhancing drug retention and absorption in nasal and oral delivery systems, potentially laying the groundwork for future product development.
- Technology Application Potential: The patent application describes formulations that could support the delivery of vaccines, biologics, and anti-inflammatory drugs, indicating that Polyrizon's technology has broad application potential across various therapeutic areas, which may attract interest from the pharmaceutical industry.
- Enhanced Market Competitiveness: By improving drug retention and absorption in mucosal tissues, Polyrizon's technology is expected to strengthen its competitive position in the rapidly growing nasal drug market, thereby driving future revenue growth for the company.
- Strategic Partnership Intent: Polyrizon has also signed a memorandum of understanding to acquire up to a 20% stake in eVTOL firm Colugo, demonstrating its strategic focus on diversifying its business and investing in innovative technologies.
See More
Polyrizon Partners with European Medical Center for NASARIX™ Study
- Research Collaboration Agreement: Polyrizon has signed an agreement with a leading European university medical center to conduct a performance and characterization study of its NASARIX™ allergy blocker, aimed at validating its nasal residence time to support the assessment of its protective barrier function.
- Clinical Study Design: The study will utilize repeated measurements to evaluate the retention, distribution, and persistence of NASARIX™ in the nasal cavities of healthy participants, which is expected to provide critical data for the company's future FDA submissions.
- Regulatory Compliance: The research will adhere to applicable European regulatory frameworks, including Regulation (EU) 2017/745 (MDR) and Good Clinical Practice (GCP) standards, ensuring scientific rigor and compliance throughout the study.
- Strategic Implications: By collaborating with a leading academic institution and an experienced CRO, Polyrizon aims to enhance data quality, strengthen its competitive position in the biotech sector, and accelerate the market introduction of its products.
See More
Polyrizon Signs Agreements with Three Clinical Sites for NASARIX™ Study
- Clinical Network Expansion: Polyrizon Ltd. has signed agreements with two additional U.S. clinical sites, expanding its NASARIX™ study network to three major centers, which are expected to contribute the highest patient enrollment rates, thereby accelerating the clinical trial's progress.
- Study Design and Objectives: The upcoming multi-center clinical trial will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis, adhering to international Good Clinical Practice standards to ensure scientific rigor and compliance.
- Efficient Recruitment Advantage: CEO Tomer Izraeli stated that securing three leading clinical centers early will facilitate efficient patient recruitment and timely study execution, demonstrating the company's strong capability in executing its clinical plans.
- Innovative Product Development: NASARIX™ is an intranasal hydrogel formulation designed to create a protective barrier in the nasal cavity to block airborne allergens, potentially offering a non-pharmacological approach to allergy prevention and opening new therapeutic options in the market.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Polyrizon Signs Clinical Trial Agreement for NASARIX Allergy Blocker
- Clinical Trial Agreement Signed: Polyrizon Ltd. has signed its first Clinical Trial Agreement with a Texas-based clinical research site, marking a significant milestone in advancing its NASARIXTM Allergy Blocker from development to potential clinical validation.
- Multi-Center Study Plan: The clinical study will evaluate the safety, tolerability, and efficacy of NASARIXTM in patients with seasonal allergic rhinitis, with plans to add additional clinical sites to broaden the study's scope.
- Non-Pharmacological Innovation: NASARIXTM is an investigational intranasal formulation designed to create a protective barrier against airborne allergens, showcasing Polyrizon's innovative potential in the biomedical device sector.
- Compliance with International Standards: The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements, supporting Polyrizon's broader regulatory strategy to ensure compliance and effectiveness of the research.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
Polyrizon Receives Notice of U.S. Patent Application for Drug Delivery Technology
- Patent Application Announcement: Polyrizon announced the receipt of a U.S. patent application notice for its Trap & Target mucoadhesive polymer technology, aimed at enhancing drug retention and absorption in nasal and oral delivery systems, potentially laying the groundwork for future product development.
- Technology Application Potential: The patent application describes formulations that could support the delivery of vaccines, biologics, and anti-inflammatory drugs, indicating that Polyrizon's technology has broad application potential across various therapeutic areas, which may attract interest from the pharmaceutical industry.
- Enhanced Market Competitiveness: By improving drug retention and absorption in mucosal tissues, Polyrizon's technology is expected to strengthen its competitive position in the rapidly growing nasal drug market, thereby driving future revenue growth for the company.
- Strategic Partnership Intent: Polyrizon has also signed a memorandum of understanding to acquire up to a 20% stake in eVTOL firm Colugo, demonstrating its strategic focus on diversifying its business and investing in innovative technologies.
See More
Polyrizon Partners with European Medical Center for NASARIX™ Study
- Research Collaboration Agreement: Polyrizon has signed an agreement with a leading European university medical center to conduct a performance and characterization study of its NASARIX™ allergy blocker, aimed at validating its nasal residence time to support the assessment of its protective barrier function.
- Clinical Study Design: The study will utilize repeated measurements to evaluate the retention, distribution, and persistence of NASARIX™ in the nasal cavities of healthy participants, which is expected to provide critical data for the company's future FDA submissions.
- Regulatory Compliance: The research will adhere to applicable European regulatory frameworks, including Regulation (EU) 2017/745 (MDR) and Good Clinical Practice (GCP) standards, ensuring scientific rigor and compliance throughout the study.
- Strategic Implications: By collaborating with a leading academic institution and an experienced CRO, Polyrizon aims to enhance data quality, strengthen its competitive position in the biotech sector, and accelerate the market introduction of its products.
See More
Polyrizon Signs Agreements with Three Clinical Sites for NASARIX™ Study
- Clinical Network Expansion: Polyrizon Ltd. has signed agreements with two additional U.S. clinical sites, expanding its NASARIX™ study network to three major centers, which are expected to contribute the highest patient enrollment rates, thereby accelerating the clinical trial's progress.
- Study Design and Objectives: The upcoming multi-center clinical trial will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis, adhering to international Good Clinical Practice standards to ensure scientific rigor and compliance.
- Efficient Recruitment Advantage: CEO Tomer Izraeli stated that securing three leading clinical centers early will facilitate efficient patient recruitment and timely study execution, demonstrating the company's strong capability in executing its clinical plans.
- Innovative Product Development: NASARIX™ is an intranasal hydrogel formulation designed to create a protective barrier in the nasal cavity to block airborne allergens, potentially offering a non-pharmacological approach to allergy prevention and opening new therapeutic options in the market.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Polyrizon Signs Clinical Trial Agreement for NASARIX Allergy Blocker
- Clinical Trial Agreement Signed: Polyrizon Ltd. has signed its first Clinical Trial Agreement with a Texas-based clinical research site, marking a significant milestone in advancing its NASARIXTM Allergy Blocker from development to potential clinical validation.
- Multi-Center Study Plan: The clinical study will evaluate the safety, tolerability, and efficacy of NASARIXTM in patients with seasonal allergic rhinitis, with plans to add additional clinical sites to broaden the study's scope.
- Non-Pharmacological Innovation: NASARIXTM is an investigational intranasal formulation designed to create a protective barrier against airborne allergens, showcasing Polyrizon's innovative potential in the biomedical device sector.
- Compliance with International Standards: The trial will be conducted in accordance with international Good Clinical Practice (GCP) standards and applicable regulatory requirements, supporting Polyrizon's broader regulatory strategy to ensure compliance and effectiveness of the research.
See More
